Sun Pharma slips after Q2FY18 profit declines: 15 Nov 2017

Sun-Pharmaceutical-Industries-Ltd

Sun Pharmaceutical Industries shares slipped 2.5% after the pharma company reported consolidated results for the quarter came in mixed versus street estimates.

The company revenue for the quarter came in 3.1 % lower than the estimated figure of Rs 6,861 crore. EBITDA for the quarter came in 1.3 % higher than the estimated figure of Rs 1,357 crore.

Sun Pharmaceutical Industries consolidated revenue for the quarter came in at Rs 6,650 crore, registering 19.5% YoY decline.

EBITDA for the quarter fell by 56.6% yoy to Rs 1,375.6 crore with a corresponding margin contraction of 1767 bps. EBITDA margin for the quarter stood at 20.7%. This margin contraction was aided by 10.4% increase in its employee benefit expenses.

The PAT for the quarter came in at Rs 912.12 crore, YoY decline of 59.2%. This was due to 193% increase in its finance cost.

The stock is currently trading at Rs 513.15, down by Rs 13 or 2.47% from its previous closing of Rs 526.15 on the BSE. The scrip opened at Rs 520.5 and has touched a high and low of Rs 520.5 and Rs 510.3 respectively.

Capitalstars is an Award Winning, SEBI Registered &ISO Certified Company in Indore, they provide Equity, Commodity, Nifty & forex trading calls with profit in your trading.

Also Visit:-
capitalstars quick payment
capitalstars career

GET MORE DETAILS HERE:-

Trading Tips
Stock Tips
Stock Advisory Company
Financial Advisory company
Share Market Company
Forex trading tips
Currency Tips

* INVESTMENT & TRADING IN SECURITIES MARKET IS ALWAYS SUBJECTED TO MARKET RISKS, PAST PERFORMANCE IS NOT A GUARANTEE OF FUTURE PERFORMANCE.
* CAPITALSTARS INVESTMENT ADVISER: SEBI REGISTRATION NUMBER: INA000001647
Advertisements